Table 1.
Clinical and Neurocognitive Characteristics of the Study Cohort
| Characteristic | HIV Positive | HIV Negative |
|---|---|---|
| No. of cases | 52 | 40 |
| Male sex | 85% | 70% |
| Age, y, mean (range) | 49 (32–70) | 66 (29–91) |
| On ART at last antemortem study visit | 74% | … |
| Ever ART treated | 93% | … |
| Dideoxy-NRTI (“d-drug”) exposed | 58% | … |
| HIV-1 plasma RNA <400 copies/mL | 27% | … |
| Current CD4 count, cells/µL, median (IQR) | 71 (25–203) | … |
| Nadir CD4 count, cells/µL, median (IQR) | 69 (12–99) | … |
| CD4:CD8 ratio, median (IQR) | 0.14 (0.06–0.33) | … |
| HAND category (NN, ANI, MND, HAD) | 9, 6, 14, 11 | … |
| Global T-score, mean (SD) | 43.9 (6.9) | … |
| Global deficit score, median (IQR) | 0.4 (0.2–1.0) | … |
| Global clinical rating, median (IQR) | 5 (4–6) | … |
Abbreviations: ANI, asymptomatic neurocognitive impairment; ART, antiretroviral therapy; HAD, human immunodeficiency virus–associated dementia; HAND, human immunodeficiency virus–associated neurocognitive disorders; HIV, human immunodeficiency virus; IQR, interquartile range; MND, mild neurocognitive disorder; NN, neurocognitively normal; NRTI, nucleoside reverse transcriptase inhibitor.